October 01, 2022
1 min watch
Save
VIDEO: Opus Genetics CEO discusses IND application for retinal degeneration gene therapy
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
CHICAGO — In this Healio Video Perspective from Eyecelerator@AAO, Opus Genetics CEO Ben Yerxa discusses an upcoming investigational new drug application for OPGx-001.
OPGx-001 is designed to address mutations in the LCA5 gene that cause retinal degeneration.
“I am excited to see what gene therapy can offer to these kids who really have no other options,” Yerxa said.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Yerxa reports being the CEO of Opus Genetics.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.